Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Neutral

Analyst Rating

Strong Buy

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Buy

A

Cellectis S.A. American Depositary Shares (CLLS)

https://www.cellectis.com

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/25/2015

Market Cap

144,608,244

Shares Outstanding

71,750,000

Weighted SO

71,583,768

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

SGTX --.--%

SGTX --.--%

DMAC --.--%

NBSE --.--%

SLNO --.--%

GNFT --.--%

CYT --.--%

ERYP --.--%

ELYM --.--%

Beta

3.2220

Last Div

0.0000

Range

0.963-3.774

Chg

0.0300

Avg Vol

53880

Mkt Cap

144608244

Exch

NASDAQ

Country

FR

Phone

33 1 81 69 16 00

DCF Diff

1.3870

DCF

0.6830

Div Yield

0.0000

P/S

11.1007

EV Multiple

-1.3266

P/FV

1.2571

Div Yield %

0.0000

P/E

-2.3361

PEG

-0.1267

Payout

0.0000

Current Ratio

1.9157

Quick Ratio

1.9157

Cash Ratio

0.9337

DSO

738.3776

DIO

0.0000

Op Cycle

738.3776

DPO

448.5355

CCC

289.8421

Gross Margin

-0.1377

Op Margin

-7.5464

Pretax Margin

-8.0722

Net Margin

-6.1389

Eff Tax Rate

0.0421

ROA

-0.1964

ROE

-0.7997

ROCE

-0.3972

NI/EBT

0.7605

EBT/EBIT

1.0697

EBIT/Rev

-7.5464

Debt Ratio

0.1764

D/E

0.4833

LT Debt/Cap

0.2819

Total Debt/Cap

0.3258

Int Coverage

-20.2861

CF/Debt

0.7100

Equity Multi

2.7397

Rec Turnover

0.4943

Pay Turnover

0.8138

Inv Turnover

999999.9999

FA Turnover

0.1550

Asset Turnover

0.0320

OCF/Share

0.5651

FCF/Share

0.5446

Cash/Share

3.0228

OCF/Sales

3.9146

FCF/OCF

0.9638

CF Coverage

0.7100

ST Coverage

3.7842

CapEx Coverage

27.6251

Div&CapEx Cov

27.6251

P/BV

1.2571

P/B

1.2571

P/S

11.1007

P/E

-2.3361

P/FCF

2.9422

P/OCF

3.6634

P/CF

3.6634

PEG

-0.1267

P/S

11.1007

EV Multiple

-1.3266

P/FV

1.2571

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 16, 16:30 Cellectis annonce le tirage de la deuxième tranche de 15 millions d’euros dans le cadre du contrat de crédit conclu avec la Banque Européenne d’Investissement (la « BEI ») GlobeNewswire Inc. Jan 16, 16:30 Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB) GlobeNewswire Inc. Jan 08, 16:30 Monthly information on share capital and company voting rights GlobeNewswire Inc. Jan 08, 16:30 Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social GlobeNewswire Inc. Dec 22, 16:30 Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023 GlobeNewswire Inc. Dec 22, 16:30 Résultats de l’Assemblée Générale Mixte de Cellectis du 22 décembre 2023 GlobeNewswire Inc. Dec 22, 16:30 Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023 GlobeNewswire Inc. Dec 01, 16:30 Monthly information on share capital and company voting rights GlobeNewswire Inc. Dec 01, 16:30 Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social GlobeNewswire Inc. Nov 17, 16:30 Cellectis’ Shareholders Meeting to be Held on December 22, 2023 GlobeNewswire Inc. Nov 17, 16:30 L’Assemblée Générale Extraordinaire de Cellectis se tiendra le 22 décembre 2023 GlobeNewswire Inc. Nov 15, 02:30 Cellectis Annonce la signature de l’Accord d’Investissement Définitif avec AstraZeneca GlobeNewswire Inc. Nov 15, 02:30 Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca GlobeNewswire Inc. Nov 15, 02:30 Cellectis Annonce la signature de l’Accord d’Investissement Définitif avec AstraZeneca GlobeNewswire Inc. Nov 15, 02:30 Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca GlobeNewswire Inc. Nov 15, 02:30 Cellectis Annonce la signature de l’Accord d’Investissement Définitif avec AstraZeneca GlobeNewswire Inc. Nov 15, 02:30 Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca GlobeNewswire Inc. Nov 06, 16:30 Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023 GlobeNewswire Inc. Nov 06, 16:30 Cellectis publie ses résultats financiers du troisième trimestre 2023 GlobeNewswire Inc. Nov 03, 16:30 Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Revenue Product Segmentation